The distribution of the top 5 molecular targets in the global ADC clinical trials in bladder cancer (Figure 2D) showed that HER2, NECTIN4, immune checkpoints (PD-1), TROP2 and epidermal growth factor receptor (EGFR) were the most widely studied targets. The gene discussed is TACSTD2; the disease is urinary bladder carcinoma.